Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following its approval by the World Health Organization.In a statement, Health ...

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

WHO releases new guidelines recommending injectable lenacapavir for HIV prevention: Geneva Wednesday, July 16, 2025, 10:00 Hrs [IST] The World Health Organization (WHO) released n ...

GENEVA, 15 July 2025–Lenacapavir–a long-acting, six-monthly injectable antiretroviral medicine manufactured by Gilead Sciences–is now recommended by the World Health Organization as an additional HIV ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

South Asia has achieved its highest-ever immunization coverage for children, with notable progress in India and Nepal, ...

In Summary Kenya is selected as one of the nine early adopters to implementation of HIV prevention Drug Lenacapavir. The ...

ViiV's Cabenuva is administered every two months and was offered to HIV patients who achieved viral suppression from daily treatments.

ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...

The offering, the first IPO this year, attracted more than 32 billion dirhams ($3.5 bln) in demand for 500 million dirhams in shares. GSK seeks FDA nod for expanded use of RSV vaccine in adults ...

Kenya is among nine African countries selected to introduce Lenacapavir, a groundbreaking long-acting injectable HIV ...

WHO director general Tedros Adhanom Ghebreyesus says this new drug—which only needs to be injected twice a year—is the next ...